Overview

Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
All
Summary
Background Smokers often reject drugs as smoking cessation aids. Nonpharmacological interventions are notoriously under-evaluated. Methods We conducted a randomized clinical trial in which we compared a medication, i.e., sustained-release bupropion (Zyban®; 413 subjects), at the time of the trial the most efficacious pharmacological smoking cessation aid, with an ultrashort psychotherapeutic intervention, Psychodynamic Model Training® (366 subjects), a manual-based psychodynamically oriented 1 ½ day autosuggestion training. Outcome criterion was 12-month self-reported continuous abstinence confirmed by urine cotinine levels below the level of detection (13 ng/ml) or, in an independent analysis, by exhaled carbon monoxide of 10 ppm or less at all interviews conducted at 3, 6, and 12 months.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical University Innsbruck
Treatments:
Bupropion
Criteria
Inclusion Criteria:

- An age of at least 18 years,

- A cigarette consumption of at least 15 cigarettes per day in the last 3 months, and

- The willingness to contribute EUR 70 to the treatment costs, regardless of the
treatment modality.

Exclusion Criteria:

- Any psychiatric diagnosis except nicotine or caffeine dependence,

- Any current psychopharmacological treatment,

- Known hypersensitivity to bupropion,

- Epilepsy,

- Liver cirrhosis,

- Brain tumor,

- Pregnancy (verified by an immunological test at the intake interview and 3 weeks after
the first day of the first menses occurring within treatment),

- Lactation,

- Any serious or unstable cardiac,

- Renal,

- Hypertensive,

- Pulmonary,

- Endocrine, or neurologic disorder,

- Ulcers,

- Dermatologic disorders,

- Current use of other smoking cessation treatments, and

- Regular use of any noncigarette tobacco product